Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Choi, J. W.
  • Gardell, S. E.
  • Herr, D. R.
  • Rivera, R.
  • Lee, C. W.
  • Noguchi, K.
  • Teo, S. T.
  • Yung, Y. C.
  • Lu, M.
  • Kennedy, G.
  • Chun, Jerold

publication date

  • January 2011

journal

  • Proceedings of the National Academy of Sciences of the United States of America  Journal

abstract

  • Sphingosine 1-phosphate (S1P), a lysophospholipid, has gained relevance to multiple sclerosis through the discovery of FTY720 (fingolimod), recently approved as an oral treatment for relapsing forms of multiple sclerosis. Its mechanism of action is thought to be immunological through an active phosphorylated metabolite, FTY720-P, that resembles S1P and alters lymphocyte trafficking through receptor subtype S1P(1). However, previously reported expression and in vitro studies of S1P receptors suggested that direct CNS effects of FTY720 might theoretically occur through receptor modulation on neurons and glia. To identify CNS cells functionally contributing to FTY720 activity, genetic approaches were combined with cellular and molecular analyses. These studies relied on the functional assessment, based on clinical score, of conditional null mouse mutants lacking S1P(1) in CNS cell lineages and challenged by experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. All conditional null mutants displayed WT lymphocyte trafficking that responded normally to FTY720. In marked contrast, EAE was attenuated and FTY720 efficacy was lost in CNS mutants lacking S1P(1) on GFAP-expressing astrocytes but not on neurons. In situ hybridization studies confirmed that astrocyte loss of S1P(1) was the key alteration in functionally affected mutants. Reductions in EAE clinical scores were paralleled by reductions in demyelination, axonal loss, and astrogliosis. Receptor rescue and pharmacological experiments supported the loss of S1P(1) on astrocytes through functional antagonism by FTY720-P as a primary FTY720 mechanism. These data identify nonimmunological CNS mechanisms of FTY720 efficacy and implicate S1P signaling pathways within the CNS as targets for multiple sclerosis therapies.

subject areas

  • Animals
  • Astrocytes
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental
  • Female
  • Fingolimod Hydrochloride
  • Gene Expression Regulation
  • Immunosuppressive Agents
  • Lymphocytes
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Multiple Sclerosis
  • Propylene Glycols
  • Receptors, G-Protein-Coupled
  • Receptors, Lysosphingolipid
  • Signal Transduction
  • Sphingosine
scroll to property group menus

Research

keywords

  • G protein-coupled receptor
  • knockout
  • lysophospholipid
  • neuroprotection
scroll to property group menus

Identity

PubMed Central ID

  • PMC3021041

International Standard Serial Number (ISSN)

  • 0027-8424

Digital Object Identifier (DOI)

  • 10.1073/pnas.1014154108

PubMed ID

  • 21177428
scroll to property group menus

Additional Document Info

start page

  • 751

end page

  • 756

volume

  • 108

issue

  • 2

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support